The National Institutes of Health (NIH) unit of the National Institute of Allergy and Infectious Diseases (NIAID) has ...

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of synthetic T cell-priming ...

A core task in single-cell data analysis is recovering the latent dimensions encoding the genetic and epigenetic landscapes inhabited by cell types and lineages. However, consensus is lacking for ...

Research shows Fc–IL-4 revitalizes exhausted CD8+ T cells, boosting antitumor responses and highlighting the potential of ...

Human innate immune cells that “remember” previous stimulation could provide new insights into chronic inflammatory diseases.

Driving the Amyloid Cascade? A microglial subtype, Mic.12, promotes plaque deposition, while another, Mic.13, promotes ...

2 Whether ILA precedes TMI or represents distinct GCA subsets is unclear ... TABs with TMI expressed markers of T lymphocytes and macrophages while they were revealed to be heterogeneous regarding the ...

“Our discovery of RORB for these selectively vulnerable cells gives us the opportunity to study in detail exactly why they ...

Researchers discovered that SARS-CoV-2-specific T and B cells in long COVID patients are maintained for two years, similar to fully recovered individuals, offering insights into long-term immunity.

Department of Medical Oncology, Erasmus MC, Rotterdam, the Netherlands. *Corresponding Author: Reno Debets, Laboratory of Tumor Immunology, Department Medical Oncology, Erasmus MC Cancer Institute, Be ...